Logo image of CELZ

CREATIVE MEDICAL TECHNOLOGY (CELZ) Stock Fundamental Analysis

NASDAQ:CELZ - Nasdaq - US22529Y4089 - Common Stock - Currency: USD

2.2  0 (0%)

Fundamental Rating

3

Taking everything into account, CELZ scores 3 out of 10 in our fundamental rating. CELZ was compared to 559 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for CELZ as it has an excellent financial health rating, but there are worries on the profitability. CELZ is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CELZ had negative earnings in the past year.
In the past year CELZ has reported a negative cash flow from operations.
In the past 5 years CELZ reported 4 times negative net income.
CELZ had a negative operating cash flow in each of the past 5 years.
CELZ Yearly Net Income VS EBIT VS OCF VS FCFCELZ Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M -20M -30M

1.2 Ratios

With a Return On Assets value of -72.96%, CELZ is not doing good in the industry: 65.65% of the companies in the same industry are doing better.
The Return On Equity of CELZ (-75.55%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -72.96%
ROE -75.55%
ROIC N/A
ROA(3y)-61.52%
ROA(5y)-1011.99%
ROE(3y)-67.22%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CELZ Yearly ROA, ROE, ROICCELZ Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2K -2K -4K

1.3 Margins

CELZ's Gross Margin of 60.00% is fine compared to the rest of the industry. CELZ outperforms 78.89% of its industry peers.
In the last couple of years the Gross Margin of CELZ has declined.
The Profit Margin and Operating Margin are not available for CELZ so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 60%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y10.52%
GM growth 5Y-3.2%
CELZ Yearly Profit, Operating, Gross MarginsCELZ Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20K -20K -40K -60K

More info and screens

7

2. Health

2.1 Basic Checks

CELZ does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CELZ has more shares outstanding
CELZ has more shares outstanding than it did 5 years ago.
There is no outstanding debt for CELZ. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CELZ Yearly Shares OutstandingCELZ Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M
CELZ Yearly Total Debt VS Total AssetsCELZ Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

Based on the Altman-Z score of -0.57, we must say that CELZ is in the distress zone and has some risk of bankruptcy.
CELZ's Altman-Z score of -0.57 is fine compared to the rest of the industry. CELZ outperforms 61.54% of its industry peers.
There is no outstanding debt for CELZ. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.57
ROIC/WACCN/A
WACC9.55%
CELZ Yearly LT Debt VS Equity VS FCFCELZ Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M -20M -30M

2.3 Liquidity

A Current Ratio of 27.39 indicates that CELZ has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 27.39, CELZ belongs to the top of the industry, outperforming 96.42% of the companies in the same industry.
CELZ has a Quick Ratio of 27.38. This indicates that CELZ is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 27.38, CELZ belongs to the top of the industry, outperforming 96.42% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 27.39
Quick Ratio 27.38
CELZ Yearly Current Assets VS Current LiabilitesCELZ Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for CELZ have decreased by -2.42% in the last year.
Looking at the last year, CELZ shows a small growth in Revenue. The Revenue has grown by 7.69% in the last year.
The Revenue for CELZ have been decreasing by -42.17% on average. This is quite bad
EPS 1Y (TTM)-2.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-13.7%
Revenue 1Y (TTM)7.69%
Revenue growth 3Y-50.37%
Revenue growth 5Y-42.17%
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 31.50% on average over the next years. This is a very strong growth
CELZ is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 544.50% yearly.
EPS Next Y44.19%
EPS Next 2Y21.33%
EPS Next 3Y41.36%
EPS Next 5Y31.5%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y1517.11%
Revenue Next 5Y544.5%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CELZ Yearly Revenue VS EstimatesCELZ Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2027 2028 2029 2030 2031 20M 40M 60M 80M 100M
CELZ Yearly EPS VS EstimatesCELZ Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 20 40 60 80

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CELZ. In the last year negative earnings were reported.
Also next year CELZ is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CELZ Price Earnings VS Forward Price EarningsCELZ Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CELZ Per share dataCELZ EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as CELZ's earnings are expected to grow with 41.36% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.33%
EPS Next 3Y41.36%

More info and screens

0

5. Dividend

5.1 Amount

CELZ does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CREATIVE MEDICAL TECHNOLOGY

NASDAQ:CELZ (6/12/2025, 8:00:00 PM)

2.2

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-09 2025-05-09/amc
Earnings (Next)08-07 2025-08-07
Inst Owners1.75%
Inst Owner Change575.11%
Ins Owners0.81%
Ins Owner Change0%
Market Cap5.70M
Analysts82.86
Price Target26.52 (1105.45%)
Short Float %0.63%
Short Ratio0.23
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-65.39%
Min EPS beat(2)-74.29%
Max EPS beat(2)-56.49%
EPS beat(4)1
Avg EPS beat(4)-36.71%
Min EPS beat(4)-74.29%
Max EPS beat(4)13.49%
EPS beat(8)3
Avg EPS beat(8)-15.09%
EPS beat(12)5
Avg EPS beat(12)-59.6%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-13.33%
EPS NQ rev (1m)-57.5%
EPS NQ rev (3m)-16.67%
EPS NY rev (1m)0%
EPS NY rev (3m)9.38%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 407
P/FCF N/A
P/OCF N/A
P/B 0.71
P/tB 0.75
EV/EBITDA N/A
EPS(TTM)-3.81
EYN/A
EPS(NY)-1.96
Fwd EYN/A
FCF(TTM)-2.32
FCFYN/A
OCF(TTM)-2.32
OCFYN/A
SpS0.01
BVpS3.11
TBVpS2.92
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -72.96%
ROE -75.55%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 60%
FCFM N/A
ROA(3y)-61.52%
ROA(5y)-1011.99%
ROE(3y)-67.22%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y10.52%
GM growth 5Y-3.2%
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 27.39
Quick Ratio 27.38
Altman-Z -0.57
F-Score5
WACC9.55%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-2.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-13.7%
EPS Next Y44.19%
EPS Next 2Y21.33%
EPS Next 3Y41.36%
EPS Next 5Y31.5%
Revenue 1Y (TTM)7.69%
Revenue growth 3Y-50.37%
Revenue growth 5Y-42.17%
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y1517.11%
Revenue Next 5Y544.5%
EBIT growth 1Y-11.67%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y40.4%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y40.4%
OCF growth 3YN/A
OCF growth 5YN/A